Latest News
Alnylam Pharmaceuticals, Inc.
- Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Hun
- Alnylam Pharmaceuticals, Inc Estimates – GETTEX:DUL
- Alnylam plots pivotal study of RNAi therapy for Huntington's disease
- Alnylam says Huntington’s drug shows promise in early study
- Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum
- Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
- Alnylam Pharmaceuticals (NDQ:ALNY): This RNAi Pioneer Is Becoming A Cardiometabolic Heavyweight Right Before Our Eyes
- Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%
- Form 144 ALNYLAM PHARMACEUTICALS For: 2 October By Investing.com
- What's behind Alnylam Pharmaceuticals's latest 3.5% stock pullback?
- Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)
- The next Alnylam? RNAi biotech City Therapeutics files for IPO
Headlines from the last 30 days, linking to the original publishers. See all market news →